35 S]sulfate into total and specific types of serum glyeosaminoglycans was studied in rats with acute, subacute or chronic liver injury (liver cirrhosis), and compared with that of normal rats. The macromolecular (protein-bound) nature of serum glyeosaminoglycans in normal and diseased animals was also analysed. The results show a strong increase in rate and extent of [ In comparison with serum glyeosaminoglycans the labeling profile of glyeosaminoglycans in the cirrhotic liver was quite different (heparan sulfateidermatan sulfate:chondroitin sulfate = 1:0.34:0.09) and changed only insignificantly during a l h labeling period.
Introduction
Previous studies on the metabolism of hepatic glycosaminoglycans have shown that rat liver slices synthesize predominantly heparan sulfate and to a much smaller degree chondroitin sulfate, hyaluronic acid and akeratan sulfate-like fraction (1, 2) . Both normal and damaged liver parenchyma, however, seem to be unable to incorporate[ ! 4 C]amino sugar into dermatan sulfate (1) (2) (3) , although the latter is present in normal liver and shows a high accumulation in injured liver tissue (4) (5) (6) (7) (8) .
Consequently the hypothesis was put forward that dermatan sulfate is synthesized in extrahepatic tissues, secreted and transported in the serum and taken up by the liver (3, 9) . Because such a metabolic pathway would be of great importance for the pathogenesis of the fibrotic transition of chronically injured liver tissue, we studied the metabolism of total and specific types of sulfated glycosaminoglycans in serum of normal and liver-injured rats, compared it with that in liver. In addition, we investigated the structure of the macromolecular, in particular protein-bound nature of serum glycosaminoglycans.
Materials and Methods

Materials
Chondroitin AC (EC 4.2.2.5) and ABC (EC 4.2.2.4) lyases were obtained from Seikagaku Kogyo Comp., Tokyo, Japan; papain (EC 3.4.22.2, crystalline suspension, 30 U/mg protein) was from Boehringer Mannheim GmbH, Germany; thioacetamide p.a. was from Merck AG, Darmstadt, Germany ;D-[l- 14 C]glucosamine hydrochloride (288.6 GBq/mol) and sodium [ 3S S]sulfate (carrier free) were from New England Nuclear Corp., Boston, USA; Sephadex G-100 and Sepharose CL-4B were from Pharmacia, Uppsala, Sweden; Dowex 1X2 and Bio-Gel P 2 were from BioRad Laboratories, Munich, Germany.
Treatment of rats
Male Sprague-Dawley rats (250-320 g s Zentralinstitut fur Verŝ uchstiere, Hannover, FRG) received food and water ad libitum. Acute liver injury was induced by two repeated intraperitoneal thioacetamide injections of 100 mg/kg in a 24 h interval. One day after the last injection the rats were sacrificed. Subacute and chronic liver injury was produced by oral administration of thioacetamide for 4 weeks and 10 months, respectively, as described previously (2) .
In general, each value represents the mean of two to four independent experiments. . ]glucosamine hydrochloride and decapitated at various times thereafter. 1-2 ml of blood was collected from the neck vessels and non-hemolytic serum produced. The serum proteins were precipitated by addition of 5 vol. of acetone, centrifuged for 5 min at 3000 £ and delipidized by washing consecutively with 5 vol. of acetone, chloroform-methanol (volumes, 200 ml + 100 ml) and ethanol-ether (volumes, 300 ml + 100 ml). The final sediment was dried at 60 °C, homogenized in 3 ml of papain-buffer (10) from which an aliquot was taken for the determination of protein (11) and proteolysed for 24 h by the addition of 300 μ\ (90 U) of papain (1) . Total glycosaminoglycans were isolated from the proteolysate (1), dissolved in water and an aliquot was taken for the determination of [ 
Determination of the incorporation of isotopes into total glycosaminoglycans of serum
Determination of the incorporation of isotopes into total glycosaminoglycans of liver
After injection of the isotope the liver was quickly removed, chilled and minced in ice-cold buffer (0.05 mol/1 tris-HCl, pH 7.6 (20 °C), 0.08 mol/1 KC1, 0.0125 mol/1 MgCl 2 ), freed carefully of blood and homogenized at 2 °C. The protein was precipitated with 5 vol. of acetone and defatted and proteolysed as above. Glycosaminogly can-associated radioactivity .was isolated and counted as described for serum.
Determination of the incorporation of isotopes into specific types of glycosaminoglycans of serum and liver As described elsewhere (1) total glycosaminoglycans were subjected to enzymatic analysis with chondroitin ABC and AC lyases to determine the incorporation of label into chondroitin sulfate and dermatan sulfate, and degraded by nitrous acid to quantitate the incorporation into heparan sulfate and heparin. The incorporation of radioactivity into specific types of glycosaminoglycans was expressed as percentage of the activity of the unfractionated glycosaminoglycans. Total labeled glycosaminoglycans of serum were chromato* graphed on a column (0.6 X 13 cm) of Dowex 1X2 (CD by stepwise elution with an increasing molarity of NaCl (1, 12) . The fractions were dialyzed, dried, dissolved in water and subjected to enzymatic and chemical identification.
Gel chromatography of serum glycosaminoglycans 13 ml of serum from normal rats, which received [^5S]sulfate 5 h prior to decapitation, were applied to a column (1.4 X 60 cm) of Bio-Gel P 2 and eluted with high ionic strength buffer A (0.02 mol/1 Tris-HCl, pH 7.6 (20 °C), 0.5 mol/1 KC1, 0.003 mol/1 MgClj). The excluded radioactivity was concentrated by ultrafiltration (filter UM 2, Amicon GmbH) and rechromatographed on a column (2 X 120 cm) of Sepharose CL-4B. The activity eluted with buffer A between 300 and 325 ml was pooled, dialyzed and divided in two equal portions. One portion wasrechiomatographed on a column (2 X 120 cm) of Sephadex G-100 after proteolytic digestion with 200 μΐ (60 U) of papain for 48 h at 60 °C, the other one was treated identically but without addition of papain. The eluates were fractionated into 5 ml portions and analysed foi radioactivity. All Chromatographie procedures were performed at 4 °C.
Density gradient centrifugation of serum glycosaminogiycans
The undigested radioactive material eluted with buffer A between 125 and 150 ml from Sephadex G-100 was concentrated by ultrafiltration (filter PM 10) and adjusted to a starting density of 1.55 kg/i by the addition of solid CsCl 2 . The gradients (13 ml) were centrifuged for 60 h at 155 000£ and 20 °C and then fractionated into 1 ml portions in which the density and radioactivity were determined. The fraction containing the peak activity was proteolysed and subjected to enzymatic analysis for chondroitin sulfate.
Electrophoresisof[
3S S]-Iabeled serum components Serum was obtained from normal rats which recived [ 3S S]-sulfate 5 h before exitus. The proteins were separated by cellulose acetate foil electrophoresis following standard clinical laboratory procedures (13) . The bands of more than 20 electropherograms were cut out, pooled arid counted for radioactivity after addition of Instagel (Packard). 
Time course of[ 3S S]sulfate incorporation into serum glycosaminoglycans of normal and liver-damaged rats
Only [
35 S]sulfate is incorporated both into liver and serum dermatan sulfate. Consequently this type of isotopic precursor was used in the following studies. Rate and extent of incorporation of sulfate into glycosaminoglycans are significantly augmented in acutely liver-damaged rats. 5 h after application of the isotope the activity of total serum glycosaminoglycans was over 4 times higher than normal ( fig. 1 ).
In contrast, long-und middle-term liver damage resulted in a 30% and 75% reduction of the respective final activities of serum glycosaminoglycans ( fig. 1 ).
The differences in the kinetics of sulfate incorporation into serum glycosaminoglycans of rats in different stages of liver injury become more complex if the timedependency of the labeling pattern of specific types of glycosaminoglycans is analysed ( fig. 2) . In normal rats a fraction of 0.65 of the sulfate incorporated within 15 min into serum glycosaminoglycans was found in chondroitin sulfate, the remainder being associated with dermatan sulfate. Concomitantly with a further time-dependent increase in the fraction of chondroitin [ (fig. 2 a) . No other sulfated glycosaminoglycans could be detected in.serum in significant amounts.
In rats with acute liver injury the proportion of initially '[ as that of dermatan sulfate was lower (about 0.10) than normal. During a 5 h period the relative distribution did not change significantly ( fig. 2b ).
In animals with subacute and chronic liver damage the initial sulfation pattern was reversed, i.e. the fraction of labeled dermatan sulfate was greater than that of chondroitin sulfate ( fig. 2c, d) 
Time course of [ 3 * S]sulfate incorporation into liver glycosaminoglycans
The kinetics of sulfation of glycosaminogjycans in serum was studied in comparison to that in liver of injured rats. Figure 3 a demonstrates a highly active sulfation of glycosaminoglycans in liver which is detectable as early as 2 min after application of the isotope. In contrast, the sulfation of glycosaminoglycans in 1-2 ml of serum (protein concentration about 70 g/1) was not detectable until 10 min after injection of the label. At this time the activity (Bq/mg protein) of total glycosaminoglycans in the liver was about 125 times higher than in serum (tab. 2).
Tab. 2. Ratio of incorporation of [
3δ S ] sulfate into glycosaminoglycans of liver and serum of chronically liver-damaged rats. The calculation is based on the data given in fig. 3 As illustrated in figure 3b and c fig. 2d, 3c ).
The ratios of sulfation of liver-and serum-derived dermatan sulfate and chondroitin sulfate were calculated. The data summarized in table 2 indicate a much higher incorporation of sulfate into the glycosaminoglycan types of liver at any time. The liver/serum ratios exhibit a time-dependent increase for dermatan sulfate but a decrease for chondroitin sulfate.
Proteoglycan character of serum glycosaminoglycans
Results presented above demonstrate metabolic changes of serum glycosaminoglycans in rats with experimental liver injury. Further studies were performed to analyse the macromolecular and protein-bound nature of serum glycosaminoglycans and its possible alteration in liverdamaged animals. The animals were decapitated 5 h after injection of [ 3S SJ sulfate and blood was collected. 13 ml of serum was applied to a column of Biogel P 2 and eluted with buffer A (0.02 mol/1 Tris-HCl, pH 7.6, 0.5 mol/1 KC1, 0.003 mol/1 MgCl 2 ). The activity eluted between 50 and 70 ml (a) was lechromatographed on a column of sepharose CL -4 B in buffer A (b). The fractions between 300 and 325 ml effluent were pooled and divided in two equal portions (a and b). Portion a was digested with papain prior to chromatography on Sephadex G 100 (d); portion b was treated identically but without addition of papain (c). The inset in c represents the distribution of the undigested chondroitin sulfate in 13 ml of a CsCl-density gradient (· ·, density).
J. Clin.Chem.Clin. Biochem. / Vol. 18, 1980/No. 5 molecular weight fractions was observed after proteolytic treatment. The elution pattern of the undegraded chondroitin sulfate (Kav = 0.05) ( fig. 5c ) and degraded chondroitin sulfate (Kav = 0.55) ( fig. 5d) was not changed by the addition of excessive amounts of unlabeled chondroitin sulfate and rat serum protein, respectively. It should be emphasized that after proteolysis a major radioactive peak of unknown identity occurred at V t (380 ml) of Sephadex G-100 ( fig. 5 d) .
The high molecular weight fraction of serum glycosaminoglycans, which was almost excluded from Sephadex G-100 ( fig. 5c ), was further characterized by isopycnic density gradient centrifugation under both associating and dissociating conditions (in the presence of 4 mol/1 of guanidinium hydrochloride).
In each case a fraction of about 0.90 of the total chondroitin sulfate banded near the top of the gradient at a density of d = 1.44 kg/1 (inset in fig. 5 c) . Neither the gel Chromatographie elution pattern of serum glycosaminoglycans nor their distribution in isopycnic gradients showed any change under the influence of liver injury (results not shown).
However, differences were observed in the ion-exchange Chromatographie behaviour of [ 35 S] glycosaminoglycans from serum of normal and acutely liver-injured rats. C]glucosamine into chondroitin sulfate. The source of serum glycosaminoglycans is unknown but it was suggested that they may derive at least in part from leukocytes or platelets (21, (23) (24) (25) or orginate from the extracellular matrices of various tissues. The sites of degradation (e.g. desulfation) of the different types of serum glycosaminoglycans are also not known but obviously glycosaminoglycan-degrading tissues are widespread in the body (26) . Several studies indicate that the liver might have an important function in this process (26, 27) .
Information on the concentration, composition and metabolism of glycosaminoglycans in serum of patients with liver disease or in serum of experimentally liverinjured rats is lacking. But from the increase of the urinary excretion of glycosaminoglycans in patients with chronic hepatitis or florid cirrhosis (28) concomitant alterations of the concentration and composition of glycosaminoglycans in serum can be deduced. (1, 2, 29) . It might be possible that an as yet unidentified extrahepatic factor which promotes specifically the synthesis or sulfation of dermatan sulfate in liver is lacking in vitro, but it also seems likely that hepatic dermatan sulfate is supplied to the liver from extrahepatic sources. The present results indirectly support this assumption, since in vivo a fraction of about 0.15 of total liver [ 3s S]glycosaminoglycan activity is located in dermatan sulfate; also significant changes of the kinetics of sulfation of serum dermatan sulfate occur in chronically liverinjured rats, and the liver/serum ratio of dermatan [ 35 S] sulfate increases with time nearly 3-fold, whereas that of chondroitin sulfate and of total gjycosaminogjycan declines (tab. 2). However, the specificity of these serum changes for liver injury remains to be deterihiried. From the data given in figure 3 the amount of labeled dermatan sulfate in the whole liver and in the total serum volume of a rat (320 g body wt.) can be calculated, based on a rat plasma volume of 39 ml/kg body weight (30), a serum protein con* centration of 70 g/1 and a total liver protein of 1. ]hexosamine, its sulfate groups must turn over more rapidly than, and independently from, the carbohydrate chain. Thus incorporation of sulfate in this type of glycosaminoglycan does not represent "de novo" synthesis, but sulfation of an already existing carbohydrate acceptor.
The experimental evidence for a supply of the carbohydrate chain acceptor to the liver via the systemic circulation, as suggested here, is rather circumstantial. Studies on the uptake and deposition of proteodermatan sulfate in normal and diseased liver, where it cannot be degraded by lysosomal enzymes (31, 32) , are difficult at present, because homologous liver or serum proteodermatan sulfate is not available in amounts sufficient for intravenous injections or application to the medium of isolated perfused rat livers. The use of a glycosaminoglycan instead of native proteoglycan for such studies might lead to erroneous results since the metabolism of both types is quite different if injected intravenously (33, 34) . y In the present study the macromolecular nature of serum glycosaminoglycans was shown, which confirms the results of earlier reports (20, 21, 23, 35) . Although glycosaminoglycans can interact electrostatically with a number of serum proteins (36) a covalent linkage to protein (core protein) seems likely since chondroitin sulfate radioactivity could not be displaced from protein by high amounts of the unlabeled counterpart ( fig. 5c) . Furthermore, the readdition of serum protein to the glycosaminoglycan obtained after proteolysis was without effect on their gel Chromatographie elution pattern ( fig. 5 d) . The large amount of low molecular weight [ 35 S] labeled material liberated by proteolysis (eluting at V t , fig.  5d ) was not characterized further. It might partially originate from [ 35 S]sulfate entrapped by undegraded serum proteins, although chromatography was performed in buffers of high ionic strength. The material, however, might also derive from [ 35 S] containing oligosaccharides covalently linked to serum proteins. It is noteworthy that liver damage does not affect the macromolecular composition of serum glycosaminoglycans, but some changes in the carbohydrate chain occur as indicated by the differences in the ion exchange Chromatographie elution profiles ( fig. 6 ).
